secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001104659-25-111979
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech Q3 net revenue up 20.5% to $17.6M; net income $3.7M vs prior loss
--------------------------------------------------------------------------------

- Net revenue $17.6M (Q3 2025) vs $14.6M (Q3 2024), driven by dermatology product sales.
- Net income attributable to common stockholders $3.7M ($0.13 basic EPS) vs net loss of $15.0M in Q3 2024.
- Cash and equivalents $86.2M as of Sep 30, 2025, up from $57.3M at Dec 31, 2024.
- Checkpoint sale to Sun Pharma closed May 2025; Fortress received ~$28M upfront plus up to $4.8M CVR and 2.5% royalty on UNLOXCYT sales.
- Dotinurad Phase 3 trials dosed Oct 2025; Crystalys raised $205M Series A; Urica (Fortress sub) holds equity and 3% royalty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/0001104659-25-111979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-111979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer